Engineered immune cells take on tough lupus cases
NCT ID NCT07432334
First seen Feb 28, 2026 · Last updated May 02, 2026 · Updated 8 times
Summary
This early-stage trial tests a treatment called CD19 CAR T-cell therapy for people with severe lupus that hasn't improved with standard medicines. The therapy uses a patient's own immune cells, which are modified in a lab to better target and attack lupus-causing cells. The main goal is to check if the treatment is safe and tolerable in 8 adults aged 16 to 55.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Vinmec Research Institute of Stem Cell and Gene Technology
Hanoi, 10000, Vietnam
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.